古塞奇尤单抗治疗银屑病关节炎的比较有效性:系统文献综述与网络Meta分析更新
该网络Meta分析更新纳入COSMOS试验数据及瑞莎珠单抗、乌帕替尼两个关键对照,系统检索至2021年2月的随机对照试验并手工检索至2021年7月的新药。结果显示古塞奇尤单抗Q8W和Q4W在ACR 20上与多数靶向药物相当,PASI 90优于多数药物,vdH-S两剂量排名较高,SAEs与多数药物相当。
要点
- 古塞奇尤单抗Q8W和Q4W的ACR 20应答与瑞莎珠单抗、乌帕替尼及多数靶向药物相当(可信区间重叠)。
- 古塞奇尤单抗Q8W和Q4W的PASI 90优于包括皮下TNF抑制剂和JAK抑制剂在内的多种药物。
- vdH-S方面古塞奇尤单抗Q4W优于瑞莎珠单抗,Q8W与瑞莎珠单抗相似,两剂量排名均高于多数药物。
核心结论
- 古塞奇尤单抗的皮肤疗效优于大多数其他靶向银屑病关节炎治疗,包括乌帕替尼。
- vdH-S方面古塞奇尤单抗两剂量与大多数治疗相当,且两剂量排名均高于多数治疗,包括乌帕替尼和瑞莎珠单抗。
- 古塞奇尤单抗两剂量的ACR应答与大多数其他药物相当,包括乌帕替尼和瑞莎珠单抗,且在网络中SAEs排名有利。
研究设计与样本
- 系统文献综述检索截至2021年2月的随机对照试验,并手工检索截至2021年7月的新药。
- 采用贝叶斯网络Meta分析比较ACR应答、PASI应答、改良van der Heijde-Sharp(vdH-S)评分和严重不良事件(SAEs)。
- 本次更新纳入古塞奇尤单抗COSMOS试验数据及瑞莎珠单抗和乌帕替尼两个关键对照。
主要发现
- ACR 20方面,古塞奇尤单抗100 mg每8周(Q8W)和每4周(Q4W)与大多数其他药物相当(即可信区间重叠),包括瑞莎珠单抗、乌帕替尼、皮下TNF抑制剂和大多数IL-17A抑制剂。
- PASI 90方面,古塞奇尤单抗Q8W和Q4W优于多种药物,包括皮下TNF抑制剂和JAK抑制剂。
- vdH-S方面,古塞奇尤单抗Q8W与瑞莎珠单抗相似,而Q4W优于瑞莎珠单抗;两剂量与大多数其他药物相当。
- 大多数药物的SAEs相当。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA). The objective of this NMA update was to include new guselkumab COSMOS trial data, and two key comparators: the IL-23 inhibitor risankizumab and the Janus kinase (JAK) inhibitor upadacitinib. MATERIAL AND METHODS: A systematic literature review was conducted to identify randomized controlled trials up to February 2021. A hand-search identified newer agents up to July 2021. Bayesian NMAs were performed to compare treatments on ACR response, Psoriasis Area and Severity Index (PASI) response, modified van der Heijde-Sharp (vdH-S) score, and serious adverse events (SAEs). RESULTS: For ACR 20, guselkumab 100 mg every 8 weeks (Q8W) and every 4 weeks (Q4W) were comparable (i.e. overlap in credible intervals) to most other agents, including risankizumab, upadacitinib, subcutaneous TNF inhibitors and most IL-17A inhibitors. For PASI 90, guselkumab Q8W and Q4W were better than multiple agents, including subcutaneous TNF and JAK inhibitors. For vdH-S, guselkumab Q8W was similar to risankizumab, while guselkumab Q4W was better; both doses were comparable to most other agents. Most agents had comparable SAEs. CONCLUSIONS: Guselkumab demonstrates better skin efficacy than most other targeted PsA therapies, including upadacitinib. For vdH-S, both guselkumab doses are comparable to most treatments, with both doses ranking higher than most, including upadacitinib and risankizumab. Both guselkumab doses demonstrate comparable ACR responses to most other agents, including upadacitinib and risankizumab, and rank favourably in the network for SAEs.
引用
- Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023. PMID: 36102818. doi:10.1093/rheumatology/keac500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。